HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme

被引：0
作者：
M. Herranz
M. E. Padín-Iruegas
Nieves Martínez-Lago
S. Aguín Losada
P. Raña-Díez
E. Brozos Vázquez
J. J. Carrera
J. R. Antúnez
A. Ruibal
R. López-López
机构：
[1] Hospital Clínico Universitario. Fundación Tejerina,Nuclear Medicine Department, Molecular Imaging Program, IDIS, USC
[2] University of Vigo,Department of Functional Biology and Health Sciences, Human Anatomy and Embryology Section
[3] Hospital Clínico Universitario,Medical Oncology Department
[4] Hospital Clínico Universitario,Pathology Department
来源：
Molecular Neurobiology | 2016年 / 53卷
关键词：
Glioblastoma; Epigenetics; HIN1; Outcome; Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Glioblastoma multiforme (GBM) is the most common brain tumor in adults. The role of high in normal-1 (HIN-1) as a potential biomarker in combating this disease is being described for the first time in this study. A combination of O6-methylguanine DNA methyltransferase (MGMT) and HIN-1 methylation could be a possible biomarker in therapy choice. Interestingly, survival data shows a similar trend for the methylation of MGMT and for unmethylation of HIN-1 and vice versa. Eighty-eight paraffin-embedded brain tumors were analyzed to screen methylation rates of different genes and evaluate the association between genes methylation and clinicopathologic variables. Our study is the first of its kind to indicate that MGMT and HIN-1 methylation status are inverted (97.7 % of methylated ones) and could be new markers in the study of GBM prognosis, especially in the therapy selection.
引用
收藏
页码：1802 / 1807
页数：5
相关论文
共 97 条
  • [1] Herman JG(2003)Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2042-2054
  • [2] Das PM(2004)DNA methylation and cancer J Clin Oncol 22 4632-4642
  • [3] Singal R(1999)Genomic imprinting and cancer Exp Cell Res 248 18-24
  • [4] Jirtle RL(2005)MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997-1003
  • [5] Hegi ME(2009)NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 5874-5880
  • [6] Diserens AC(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996
  • [7] Gorlia T(2001)HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells Proc. Natl. Acad. Sci. U.S.A 98 9796-801
  • [8] Hamou MF(2005)HIN-1, an inhibitor of cell growth, invasion, and AKT activation Cancer Res 65 9659-9669
  • [9] de Tribolet N(2004)Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types Mol Cancer Res 2 489-494
  • [10] Wick W(2003)Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma Clin Cancer Res 9 3042-3046
12345678910